ArticleDermatology and therapy2024

Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.

Melinda Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.